Russia to Begin Clinical Trials of New Cancer Vaccine in Coming Months

Alexander Gintsburg, Director of Russia’s Gamaleya National Research Center for Epidemiology and Microbiology, announced that the first doses of a new cancer vaccine are expected to be administered to patients within the next few months. The development marks an early experimental step toward using advanced technologies in cancer treatment.

Gintsburg stated that the vaccine initiative is being carried out in collaboration with the Russian Ministry of Health. Initial clinical trials will target a limited group of patients diagnosed with melanoma, a form of skin cancer. The first phase of testing is set to take place on a small scale.
According to Gintsburg, the Gamaleya Center is currently in the process of producing the vaccine, which will subsequently be delivered to the Herzen Moscow Oncology Research Institute and the Blokhin Cancer Center—two leading institutions in Russia specializing in oncology—for the experimental phase.

One of the key features of this vaccine, he explained, is its personalized approach. It is developed based on the individual genetic profile of each patient, making it fundamentally different from existing drugs or vaccines. As such, the vaccine is not interchangeable and is intended solely for the patient it is designed for.
Gintsburg also noted growing international interest in the research, stating that he has received over a dozen inquiries from foreign institutions regarding the new vaccine.
Read also: Potential Alternative to Hearing Aids and Cochlear Implants








